2.Comparative evaluation of commercial enzyme immuno assays for anti-HCV antibody.
Korean Journal of Blood Transfusion 1993;4(1):75-81
No abstract available.
3.Clinical review of whipple operations.
Tae Sung SOHN ; Yong Il KIM ; Chi Kyu WON
Journal of the Korean Surgical Society 1992;43(3):338-343
No abstract available.
4.Acute basophilic leukemia: a case report.
Mee Na KIM ; Hyun Sook CHI ; Cheol Won SEO
Korean Journal of Hematology 1993;28(2):403-411
No abstract available.
Leukemia, Basophilic, Acute*
5.Optimal dose of gamma irradiation for the prevention of transfusion-associated graft-versus-host disease.
Dae Won KIM ; Eun Suk KANG ; Hyun Suk CHI ; Won Ki MIN ; Chowl Won SUH
Korean Journal of Blood Transfusion 1993;4(1):67-74
No abstract available.
Graft vs Host Disease*
6.Evaluation of Striatal Dopamine Transporter Density using 123I-beta-CIT SPECT in Schizophrenic Patients Treated with Olanzapine - Pilot study.
Chul Eung KIM ; Hey Won MOON ; Won Sick CHOE ; Chang Ho KIM ; Dae Yoon CHI
Korean Journal of Nuclear Medicine 2002;36(4):224-231
No abstract available.
Dopamine Plasma Membrane Transport Proteins*
;
Dopamine*
;
Humans
;
Pilot Projects*
;
Tomography, Emission-Computed, Single-Photon*
7.Effect of thawed fresh-frozen plasma on coagulation factors according to storage period and temperature.
Dae Won KIM ; Hyun Sook CHI ; Won Ki MIN ; Chik Hyun PAI
Korean Journal of Blood Transfusion 1992;3(1):41-46
No abstract available.
Blood Coagulation Factors*
;
Plasma*
8.Seroprevalence of anti-HCV according to EIA in korean blood donors: comparison of EIA results with confirmatory tests.
Dae Won KIM ; Tae Jin HAN ; Hyun Suck CHI ; Young Sik KIM
Korean Journal of Blood Transfusion 1993;4(2):223-229
No abstract available.
Blood Donors*
;
Humans
;
Seroepidemiologic Studies*
9.Seroprevalence of anti-HCV according to EIA in korean blood donors: comparison of EIA results with confirmatory tests.
Dae Won KIM ; Tae Jin HAN ; Hyun Suck CHI ; Young Sik KIM
Korean Journal of Blood Transfusion 1993;4(2):223-229
No abstract available.
Blood Donors*
;
Humans
;
Seroepidemiologic Studies*
10.Evaluation of the Third-generation Enzyme Immunoassay and Confirmatory Test for Anti-HCV.
Dae Won KIM ; Hyun Sook CHI ; Seog Woon KWON ; In Soo KIM
Korean Journal of Blood Transfusion 1994;5(2):115-126
The ultimate goal of blood donor screening for anti-hepatitis C virus(HCV) antibodies is the specific exclusion of vital carriers from the blood donor population. Recently, a third-generation anti-HCV screening (Lucky HCD 3.0) and immunoblot assay (Lucky Confirm) using antigens derived from the core and different nonstructural regioris (NS3, NS4 and NS5) of the HCV vital genome were developed. To evaluate the usefulness of these assays, anti-HCV reaction patterns of the RIBA-2 and the presence of HCV-RNA detected by reverse transcriptase-polymerase chain reaction(RT-PCR) were examined in 180 sera, which were repeatedly positive in Abbott EIA-2, and HCV seroconversion panel sera. The reaction intensity of HCD 3.0 was higher than that of HCD 2.0. The sensitivity and positive predictive value for vital carrier state of HCD 3.0 were 98.4% and 85.4%, respectively. HCD 3.0 assay enabled the detection of the antibody response 2 weeks earlier than did other second-generation EIAs. RT-PCR testing of sera with RIBA-2-indetermihate results showed that 33.3%(10/30) had evidence of HCV-RNA. However, all of nine Lucky Confirm-indeterminate cases were negative for HCV-RNA. The sensitivity and specificity of Lucky Confirm test were 99.2% and 76.4%, respectively, and the positive and negative predictive values were 90.5% and 97.7%, respectively.
Antibodies
;
Antibody Formation
;
Blood Donors
;
Carrier State
;
Genome
;
Humans
;
Immunoenzyme Techniques*
;
Mass Screening
;
Sensitivity and Specificity
Result Analysis
Print
Save
E-mail